Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• Age ≥ 18 years
• Confirmed diagnosis of the respective NHL
• If patient is alive: signed written informed consent
‣ For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.
⁃ For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.
Locations
Other Locations
Germany
Praxis für Interdisziplinäre Hämatologie und Onkologie
RECRUITING
Freiburg Im Breisgau
Contact Information
Primary
Martina Jänicke, Dr.
rubin@iomedico.com
+4976115242
Time Frame
Start Date: 2023-09-27
Estimated Completion Date: 2033-12
Participants
Target number of participants: 2950
Treatments
Chronic Lymphocytic Leukemia (CLL)
Patients with CLL receiving systemic treatment (physician's choice)
Diffuse Large B-cell Lymphoma (DLBCL)
Patients with DLBCL receiving systemic treatment (physician's choice)
Follicular Lymphoma (FL)
Patients with FL receiving systemic treatment (physician's choice)
Mantle Cell Lymphoma (MCL)
Patients with MCL receiving systemic treatment (physician's choice)
Marginal Zone Lymphoma (MZL)
Patients with MZL receiving systemic treatment (physician's choice)
Waldenström's macroglobulinemia (WM)
Patients with WM receiving systemic treatment (physician's choice)
Related Therapeutic Areas
Sponsors
Leads: iOMEDICO AG